Dextroamphetamine sulfate is a psycho-stimulant used to treat ADHD
(attention deficit disorder with hyperactivity) in children. It is also used to treat narcolepsy, a sleep disorder. Dextroampthetmine stimulates the nervous system, and affects certain chemicals in the brain, which may help to improve attention span and behavior. On November 7, 2008, the FDA posted a press release from ETHEX
Corporation announcing the recall of its generic/non-branded dextroamphetamine tablets in the following lots: 73934, 75892, 77945, 81137, 86320 with expiration dates ranging from 6/2009 to 5/2011
These lots were recalled as a precaution, as they may contain oversized tablets, which could result in patients receiving up to twice the recommended dosage. These patients could experience some serious side effects, and even risk death. Dextroamphetamine sulfate overdose effects might include rapid heart rate and high blood pressure.
ETHEX Corporation sent its recall notifications to wholesalers and retailers that received inventory of the dextroamphetamine lots with the possible oversized tablets. The recall notices give instructions for retailers and pharmacies to contact consumers given this medication in order that they may either get replacement of the product or a refund.
According to the ETHEX Corporation press release, “The 10 mg Dextroamphetamine Sulfate Tablet is a round, flat-face, bevel edge, orange mottled tablet debossed "ETHEX" and "312" on one side and double-scored on the other side.”
Consumers who experience any adverse reactions to dextroamphetamine sulfate tablets listed in the lot numbers above should contact their healthcare providers immediately.
If you or a family member has taken dextroamphetamine sulfate tablets and experienced adverse side effects or died as a result, please fill out our Case Review Form to the right on this page for a free consultation.
Dangerous Drugs
News Articles
Pfizer Starts Media Ad Blitz to Address Smoking Drug Concerns
May 28 (Bloomberg) – Pfizer Inc.
(read more..)
North Carolina Case Claims Financial Calamity From Bayer Drug
5/2/08 - Triangle Business Journal
(read more..)
Panel May Issue Subpoenas Related to FDA Approval
on Antibiotic Drug Ketek
1/28/08 - FDA
(read more..)
Second Safety Warning on Fentanyl Skin Patch
12/21/07 - FDA
(read more..)
F.D.A. Investigates Quit-Smoking Drug
11/20/07 - Associated Press
(read
more..)
Merck to Pay $4.85 Billion To Settle Most Vioxx Cases
11/09/07 - AngelReyesBlog.com
(read
more..)
Cephalon Drug Is Tied to Several Deaths
9/14/07 - The Wall Street Journal
(read
more..)
$5.5 Million Award in First Federal Fentanyl (Duragesic) Pain Patch Trial
6/19/07 - Press Release
(read
more...)